FDA ApprovedUnited States
New Oral Pill Option for Previously Treated Bile Duct Cancer
Lyrfigtu (lirafugratinib) — oral FGFR2 inhibitor for previously treated FGFR2-altered cholangiocarcinoma
The United States approved Lyrfigtu (lirafugratinib) on 23 September 2026. It is for adults with bile duct cancer that cannot be removed or has spread, with an…
This is for adults with previously treated unresectable, locally advanced, or metastatic bile duct cancer (cholangiocarcinoma) that harbors an FGFR2 gene…